Daratumumab: A new future for AL-Amyloidosis and Multiple Myeloma

Concomitant development of symptomatic amyloid light-chain (AL) amyloidosis and multiple myeloma (MM) is rare and has a poor survival rate. Introduction of thalidomide and bortezomib, a proteasome inhibitor, has improved the survival of patients with MM; however, it has not cured the disease. Nevert...

Full description

Bibliographic Details
Main Author: Pardinhas,Clara (author)
Other Authors: Francisco,Luís (author), Escada,Luís (author), Sousa,Vítor (author), Alves,Rui (author)
Format: report
Language:eng
Published: 2020
Subjects:
Light-chain amyloidosis
Multiple Myeloma
Daratumumab
Prognosis
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692020000300008
Country:Portugal
Oai:oai:scielo:S0872-01692020000300008

Internet

http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692020000300008

Similar Items